236 related articles for article (PubMed ID: 20200350)
21. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
22. Genetics of type 2B von Willebrand disease: "true 2B," "tricky 2B," or "not 2B." What are the modifiers of the phenotype?
Othman M; Favaloro EJ
Semin Thromb Hemost; 2008 Sep; 34(6):520-31. PubMed ID: 19085651
[TBL] [Abstract][Full Text] [Related]
23. Molecular genetics of type 2 von Willebrand disease.
Fressinaud E; Mazurier C; Meyer D
Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
[TBL] [Abstract][Full Text] [Related]
24. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice.
Chen J; Reheman A; Gushiken FC; Nolasco L; Fu X; Moake JL; Ni H; López JA
J Clin Invest; 2011 Feb; 121(2):593-603. PubMed ID: 21266777
[TBL] [Abstract][Full Text] [Related]
25. A family having type 2B von Willebrand disease with a novel VWF p.R1308S mutation: Detection of characteristic platelet aggregates on peripheral blood smears as the key aspect of diagnosis.
Hatta K; Kunishima S; Suganuma H; Tanaka N; Ohkawa N; Shimizu T
Thromb Res; 2015 Oct; 136(4):813-7. PubMed ID: 26278967
[TBL] [Abstract][Full Text] [Related]
26. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease.
Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F
Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759
[TBL] [Abstract][Full Text] [Related]
27. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
[TBL] [Abstract][Full Text] [Related]
28. Type 2B von Willebrand disease with or without large multimers: A distinction of the two sides of the disorder is long overdue.
Casonato A; Daidone V; Galletta E; Bertomoro A
PLoS One; 2017; 12(6):e0179566. PubMed ID: 28640903
[TBL] [Abstract][Full Text] [Related]
29. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.
Hulstein JJ; de Groot PG; Silence K; Veyradier A; Fijnheer R; Lenting PJ
Blood; 2005 Nov; 106(9):3035-42. PubMed ID: 16014562
[TBL] [Abstract][Full Text] [Related]
30. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
31. A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
Shen MC; Lin JS; Lin DS; Hsu SC; Lin B
Thromb Res; 2003; 112(5-6):291-5. PubMed ID: 15041272
[TBL] [Abstract][Full Text] [Related]
32. 2B or not 2B? A diagnosis of von Willebrand disease a lifetime of 86 years in the making.
Chapman K; Prasad R; Mohammed S; Favaloro EJ
Blood Coagul Fibrinolysis; 2021 Apr; 32(3):229-233. PubMed ID: 33443930
[TBL] [Abstract][Full Text] [Related]
33. Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.
Tischer A; Brehm MA; Machha VR; Moon-Tasson L; Benson LM; Nelton KJ; Leger RR; Obser T; Martinez-Vargas M; Whitten ST; Chen D; Pruthi RK; Bergen HR; Cruz MA; Schneppenheim R; Auton M
J Mol Biol; 2020 Jan; 432(2):305-323. PubMed ID: 31628947
[TBL] [Abstract][Full Text] [Related]
34. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.
Jacobi PM; Gill JC; Flood VH; Jakab DA; Friedman KD; Haberichter SL
Blood; 2012 May; 119(19):4543-53. PubMed ID: 22431572
[TBL] [Abstract][Full Text] [Related]
35. Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease.
Matsubara Y; Murata M; Sugita K; Ikeda Y
J Thromb Haemost; 2003 Oct; 1(10):2198-205. PubMed ID: 14521605
[TBL] [Abstract][Full Text] [Related]
36. Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.
Dhanesha N; Prakash P; Doddapattar P; Khanna I; Pollpeter MJ; Nayak MK; Staber JM; Chauhan AK
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1829-37. PubMed ID: 27444201
[TBL] [Abstract][Full Text] [Related]
37. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
de Romeuf C; Hilbert L; Mazurier C
Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
[TBL] [Abstract][Full Text] [Related]
38. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.
Hayward CP; Moffat KA; Graf L
Int J Lab Hematol; 2014 Jun; 36(3):334-40. PubMed ID: 24750680
[TBL] [Abstract][Full Text] [Related]
39. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
Kinoshita S; Yoshioka K; Kasahara M; Takamiya O
Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773
[TBL] [Abstract][Full Text] [Related]
40. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
